You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SHR3680

Showing 1 - 19 of 19
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Castration-Resistant Prostate Cancer Trial (SHR3680 tablets)

Not yet recruiting
  • Castration-Resistant Prostate Cancer
  • SHR3680 tablets
  • (no location specified)
Nov 1, 2022

Advanced Salivary Gland Carcinoma Trial in Shanghai (SHR-A1811, SHR 3680 + leuprolide, SHR-A1921)

Not yet recruiting
  • Advanced Salivary Gland Carcinoma
  • Shanghai, China
    Dongmei Ji
Jun 21, 2023

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Trial in

Recruiting
  • Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
  • SHR3680
  • Placebo
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer center
Dec 28, 2021

Hepatic Impairment, Healthy Participants Trial in GuangZhou (SHR3680)

Recruiting
  • Hepatic Impairment
  • Healthy Participants
  • SHR3680
  • GuangZhou, Guangdong, China
    Guangzhou Eighth People'S Hospital
Nov 2, 2021

Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

Recruiting
  • Breast Cancer
  • Metastatic Cancer
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
Jul 22, 2022

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Prostate Cancer, Biochemical Recurrence Trial in Nanjing (Rezvilutamide, Androgen deprivation therapy (ADT), SRT)

Recruiting
  • Prostate Cancer
  • Biochemical Recurrence
  • Nanjing, Jiangsu, China
  • +1 more
Mar 2, 2023

Healthy Male Subjects Trial in Guanzhou (test SHR3680 tablets, reference SHR3680 tablets)

Active, not recruiting
  • Healthy Male Subjects
  • test SHR3680 tablets
  • reference SHR3680 tablets
  • Guanzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
May 24, 2021

Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or

Recruiting
  • Triple-negative Breast Cancer
  • Pyrotinib with Capecitabine
  • +6 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2022

Prostate Cancer Metastatic Trial in Chengdu (SHR3680+Docetaxel, SHR3680, Docetaxel)

Unknown status
  • Prostate Cancer Metastatic
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Feb 19, 2021

Prostate Cancer, Castration-resistant Prostate Cancer Trial in Shanghai (SHR3680, SHR2554)

Terminated
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 2, 2021

Prostate Cancer Patients Trial in Changsha (Repaglinide, Bupropion and SHR3680)

Recruiting
  • Prostate Cancer Patients
  • Repaglinide, Bupropion and SHR3680
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Dec 7, 2020

Drug-drug Interaction,SHR3680 Trial in Qingdao (SHR3680, digoxin, Rosuvastatin calcium)

Unknown status
  • Drug-drug Interaction,SHR3680
  • SHR3680
  • +3 more
  • Qingdao, China
    Affiliated Hospital of Qingdao University
Nov 4, 2020

Prostate Cancer Patients Trial in Guangzhou (Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680)

Unknown status
  • Prostate Cancer Patients
  • Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Dec 15, 2020

Prostate Cancer, Castration-resistant Prostate Cancer Trial in Shanghai (SHR3680, SHR3162, SHR3680(Placebo))

Active, not recruiting
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • SHR3680
  • +3 more
  • Shanghai, China
    Ye Dingwei
May 12, 2020

Tumor, Prostate Cancer Trial in Australia (SHR3680; SHR3162)

Completed
  • Neoplasm
  • Prostate Cancer
  • SHR3680; SHR3162
  • Albury, New South Wales, Australia
  • +5 more
Jul 20, 2020

Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma Trial in China (SHR3680)

Unknown status
  • Hormone Refractory Prostate Cancer
  • Metastatic Prostate Carcinoma
  • SHR3680
  • Beijing, Beijing, China
  • +11 more
May 12, 2020

Prostate Cancer, Hormone-Dependent Prostate Cancer Trial in Worldwide (SHR3680, Bicalutamide)

Active, not recruiting
  • Prostate Cancer
  • Hormone-Dependent Prostate Cancer
  • Burgas, Bulgaria
  • +66 more
Feb 28, 2021

Breast Cancer Trial in Shanghai (A, B, CL1)

Recruiting
  • Breast Cancer
  • A
  • +8 more
  • Shanghai, Please Select, China
  • +1 more
Nov 27, 2021